ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. Its products include Naronapride, a proprietary serotonin type 4 (5HT4) for the treatment of multiple gastrointestinal disorders, Budiodarone, a proprietary compound in Phase 2 development for the treatment of atrial fibrillation, Tecarfarin, a novel compound for oral anti-coagulation therapy, and ATI-9242, a typical antipsychotic for the treatment of schizophrenia and other psychiatric disorders. The company was founded on February 28, 1997 by Peter G. Milner and Pascal Druzgala and is headquartered in Fremont, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is the 52-week high for Aryx Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Aryx Therapeutics Inc 52 week high is $0.0012 as of June 15, 2024.
What is the 52-week low for Aryx Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Aryx Therapeutics Inc 52 week low is $0.00 as of June 15, 2024.
What is the 50-day moving average of Aryx Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Aryx Therapeutics Inc 50-day moving average is $0.00.